News
The patient in this case had been well-controlled on warfarin therapy for over 5 years following mitral valve replacement.
News
Results from a new real-world study evaluating rivaroxaban (Xarelto; Janssen), a factor Xa inhibitor, in morbidly obese patients were recently published in Thrombosis Research. The retrospective cohort study analyzed data from 2 US claims databases (Truven MarketScan Commercial Claims and Encounters database and MarketScan Medicare Supplemental database) to evaluate the clinical and health/economic outcomes of…
News
“The elevation in INR can be explained by the inhibition of CYP2C9 by cannabis use causing decreased metabolism of warfarin,” the authors explained.
News
To investigate an appropriate dosing strategy for 4F-PCC (Kcentra; CSL Behring) in obese patients, the authors conducted a retrospective analysis comparing the reversal of warfarin using adjusted (N=28) vs actual body weight (N=50).
ESC 2017
The primary safety endpoint was defined as time to major bleeding events and clinically relevant non-major bleeding events when compared to triple therapy with warfarin.
News
Patients taking apixaban showed significantly less intracranial hemorrhage (0.33% per year) vs. patients taking warfarin (0.80% per year) no matter the type and location.
News
Findings from a study published in the British Journal of Clinical Pharmacology showed that apixaban appeared to be an appropriate alternative to warfarin for patients with severe renal impairment.
News
For veterans receiving warfarin for nonvalvular atrial fibrillation, continuing warfarin after a diagnosis of dementia is associated with a protective effect in prevention of stroke and mortality, according to a study published online December 30 in the Journal of the American Geriatrics Society.
News
Co-treatment with proton-pump inhibitors (PPIs) in patients initiating warfarin was associated with reduced reduced risk of warfarin-related upper gastrointestinal (GI) bleeding, a study published in Gastroenterology reported.
News
A study published in JAMA found that warfarin use to prevent strokes in atrial fibrillation may not adequately manage blood clotting over time, despite patients having been stable on the drug.